National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 10024-10025 [2017-02727]
Download as PDF
10024
Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the prize
submissions, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Minority Health
and Health Disparities; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Minority Health and Health Disparities
Special Emphasis Panel; ZMD1 DRI (M1) NIH
Support for Conference and Scientific
Meetings (Parent R13).
Date: March 3, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20852.
Contact Person: Deborah Ismond, Ph.D.,
Scientific Review Officer, Division of
Scientific Programs, National Institute on
Minority Health and Health Disparities,
National Institutes of Health, 6707
Democracy Blvd., Suite 800, Bethesda, MD
20892, (301) 402–1366, ismonddr@
mail.nih.gov.
Dated: February 2, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02616 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sradovich on DSK3GMQ082PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The prize submissions and
VerDate Sep<11>2014
18:11 Feb 08, 2017
Jkt 241001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; OD16–137:
Antimicrobial Resistance Rapid, Point-ofNeed Diagnostic Test Challenge: Step 1.
Date: March 2–3, 2017.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate prize
submissions.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Gagan Pandya, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Rm. 3200, MSC 7808,
Bethesda, MD 20892, 301–435–1167,
pandyaga@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 3, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02619 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Center Core
Grants (P30) and Pathways to Independence
Awards (K99).
Date: March 6, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Brian Hoshaw, Ph.D.,
Scientific Review Officer, National Eye
Institute, National Institutes of Health,
Division of Extramural Research, 5635
Fishers Lane, Suite 1300, Rockville, MD
20892,
301–451–2020, hoshawb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: February 3, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02617 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID, Clinical Trial
Planning Grant (R34) and Implementation
Cooperative Agreement (U01).
Date: March 6, 2017.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institutes of Health/
NIAID, 5601 Fishers Lane, Rockville, MD
20852, 240–669–5026, haririmf@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
E:\FR\FM\09FEN1.SGM
09FEN1
Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices
Dated: February 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02727 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Inhibition of Plasmodial
Surface Anion Channels for the
Treatment or Prevention of Malaria
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Allergy and Infectious Diseases, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Commercialization
Patent License to practice the inventions
embodied in the Patents and Patent
Applications listed in the Summary
Information section of this notice to
Microbiotix, Inc. (‘‘Microbiotix’’)
located in Worcester, Massachusetts.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Allergy and Infectious Diseases’
Technology Transfer and Intellectual
Property Office on or before February
24, 2017 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Commercialization Patent
License should be directed to: Peter
Tung, Technology Transfer and Patent
Specialist, Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Suite 6D,
MSC9804, Rockville, MD 20852–9804
Telephone: (301) 496–2644; Facsimile:
(240) 627–3117; Email: peter.tung@
nih.gov.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
Intellectual Property
United States Provisional Patent
Application No. 61/083,000, filed July
23, 2008 and entitled ‘‘Inhibitors of the
Plasmodial Surface Anion Channel as
Antimalarials’’ [HHS Reference No. E–
202–2008/0–US–01]; PCT Patent
Application PCT/US09/50637, filed July
15, 2009 and entitled ‘‘Inhibitors of the
Plasmodial Surface Anion Channel as
Antimalarials’’ [HHS Reference No. E–
202–2008/0–PCT–02]; and U.S. and
VerDate Sep<11>2014
18:11 Feb 08, 2017
Jkt 241001
foreign patent applications claiming
priority to the aforementioned
applications.
United States Provisional Patent
Application No. 61/474,583, filed April
12, 2011 and entitled ‘‘Plasmodial
Surface Anion Channel Inhibitors for
the Treatment of Malaria’’ [HHS
Reference No. E–145–2011/0–US–01];
PCT Patent Application PCT/US12/
33072, filed April 11, 2012 and entitled
‘‘Plasmodial Surface Anion Channel
Inhibitors for the Treatment of Malaria’’
[HHS Reference No. E–202–2008/0–
PCT–02]; and U.S. and foreign patent
applications claiming priority to the
aforementioned applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘Methods
of preventing and/or treating malaria
infection by inhibition of Plasmodium
Surface Anion Channels (PSAC) with
anti-PSAC compounds.’’
This technology discloses a novel
anion channel on the surface of red
blood cells (RBCs) in animals infected
with Plasmodium. Named PSAC for
‘‘plasmodium surface anion channel,’’
this channel protein facilitates the
transport of nutrients into RBCs for the
plasmodium parasite. Sugars, amino
acids, purines, vitamins, and precursors
for phospholipid biosynthesis have
markedly increased uptake into infected
RBCs via PSAC. Many of these nutrients
have negligible uptake in uninfected
RBCs. PSACs, which allow nutrients to
reach the growing plasmodium parasites
inside RBCs, therefore serves as a new
target for the development of
antimalarial compounds. The disclosed
anti-PSAC compositions and methods of
using these anti-PSAC compounds
provide a means for prevention or
treatment of malaria infection by
blocking nutrients to plasmodium
parasites.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Allergy and Infectious
Diseases receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
10025
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–02673 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
Geological Survey
[17 GX17CJ00GKC0100]
Notice of an Open Meeting of the
Advisory Committee on Water
Information
United States Geological
Survey, Department of the Interior.
ACTION: Notice of an open meeting of the
Advisory Committee on Water
Information (ACWI).
AGENCY:
Notice is hereby given of a
meeting of the ACWI. This meeting is to
discuss broad policy-related topics
relating to national water initiatives,
and the development and dissemination
of water information, through reports
from ACWI subgroups. The agenda will
include updates from ACWI’s various
subcommittees, unveiling of the
strategic plan for the Water Quality
Portal for 2017–2021, a proposal for a
new Terms of Reference document for
the Subcommittee on Ground Water, a
proposal to establish a new Risk
Management Workgroup within the
Subcommittee on Hydrology, an update
on activities and accomplishments
related to the Open Water Data
Initiative, and a report on the
Hydrologic Frequency Analysis Work
Group’s progress on Bulletin 17C,
Guidelines For Determining Flood Flow
Frequency.
The ACWI was established under the
authority of the Office of Management
and Budget Memorandum M–92–01 and
the Federal Advisory Committee Act.
The purpose of the ACWI is to provide
a forum for water information users and
professionals to advise the Federal
Government on activities and plans that
may improve the effectiveness of
meeting the Nation’s water information
needs. Member organizations help to
foster communications between the
Federal and non-Federal sectors on
sharing water information.
SUMMARY:
E:\FR\FM\09FEN1.SGM
09FEN1
Agencies
[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)]
[Notices]
[Pages 10024-10025]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02727]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID, Clinical Trial Planning Grant
(R34) and Implementation Cooperative Agreement (U01).
Date: March 6, 2017.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institutes of Health/NIAID, 5601 Fishers Lane,
Rockville, MD 20852, 240-669-5026, haririmf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
[[Page 10025]]
Dated: February 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-02727 Filed 2-8-17; 8:45 am]
BILLING CODE 4140-01-P